MCID: ORL015
MIFTS: 57

Oral Squamous Cell Carcinoma malady

Categories: Rare diseases, Cancer diseases, Oral diseases, Gastrointestinal diseases

Aliases & Classifications for Oral Squamous Cell Carcinoma

About this section

Aliases & Descriptions for Oral Squamous Cell Carcinoma:

Name: Oral Squamous Cell Carcinoma 11 48 13
Squamous Cell Carcinoma of Mouth 68
 
Mouth Squamous Cell Carcinoma 11

Classifications:



External Ids:

Disease Ontology11 DOID:0050866

Summaries for Oral Squamous Cell Carcinoma

About this section
Disease Ontology:11 An oral cavity cancer that has material basis in squamous cells.

MalaCards based summary: Oral Squamous Cell Carcinoma, also known as squamous cell carcinoma of mouth, is related to squamous cell carcinoma and leukoplakia. An important gene associated with Oral Squamous Cell Carcinoma is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways are miR-148a/miR-31/FIH1/HIF1andalpha;-Notch signaling in glioblastoma and miRNAs involved in DNA damage response. Affiliated tissues include lymph node, endothelial and bone, and related mouse phenotypes are Decreased cell migration and Decreased viability.

Related Diseases for Oral Squamous Cell Carcinoma

About this section

Diseases related to Oral Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 232)
idRelated DiseaseScoreTop Affiliating Genes
1squamous cell carcinoma11.3
2leukoplakia10.5
3endotheliitis10.5
4oral leukoplakia10.5
5spondylarthropathy10.4CDKN2A, HRAS, TP53
6postpoliomyelitis syndrome10.4CDKN2A, HRAS, TP53
7linitis plastica10.4CDH1, TP53
8coronary stenosis10.4CDKN1B, TP53, VEGFA
9gallbladder pleomorphic giant cell adenocarcinoma10.4CDKN2A, HRAS, TP53
10adult epithelioid sarcoma10.4CDKN2A, HRAS, TP53
11oro-mandibular-limb hypogenesis syndrome10.4CCND1, CDKN2A, TP53
12brain stem medulloblastoma10.4CCND1, CDKN2A, TP53
13stenosis of lacrimal punctum10.4CCND1, EGFR, HRAS
14cervical verrucous carcinoma10.4CCND1, CDKN2A, TP53
15precursor t-lymphoblastic lymphoma/leukemia10.4EGFR, HRAS, PDPN
16spastic paraplegia 110.4EGFR, TP53, VEGFA
17aortic aneurysm10.4CDKN2A, VEGFA, VEGFC
18aicardi-goutieres syndrome10.4CDKN2A, HRAS, TP53
19brachydactyly tibial hypoplasia10.4CCND1, CDKN2A, PTGS2
20active vestibular meniere's disease10.4CCND1, CDKN2A, PTGS2
21facio skeletal genital syndrome rippberger type10.4MMP2, MMP9
22chronic monocytic leukemia10.4CDKN2A, EGFR, TP53
23thymus adenocarcinoma10.4EGFR, MMP2, MMP9
24acquired hemangioma10.4CDKN2A, PTGS2, TP53
25thymus squamous cell carcinoma10.4CDKN2A, EGFR, TP53
26urethral verrucous carcinoma10.4CDKN2A, PTGS2, TP53
27chondrodysplasia punctata, rhizomelic, type 110.4CDH1, MMP9, PTGS2
28tumor of exocrine pancreas10.4CDKN2A, EGFR, VEGFA
29secondary hyperparathyroidism of renal origin10.4CDKN2A, EGFR, TP53
30anal carcinoma in situ10.4CDKN2A, KRT19, TP53
31clear cell adenofibroma10.4CDKN2A, TP53
32placental site trophoblastic tumor10.4CDKN2A, TP53, VEGFA
33large cell medulloblastoma10.4CTNNB1, MMP9, VEGFA
34myxedema10.4CDKN2A, EGFR, HRAS, TP53
35breast papillary carcinoma10.4CDH1, MMP2, MMP9
36tricuspid valve prolapse10.4CDKN2A, EGFR, PTGS2
37papillary adenofibroma10.4HRAS, KRT19, TP53
38immunodeficiency due to a late component of complement deficiency10.4EGFR, TP53, VEGFA
39pityriasis rosea10.4CDKN1B, CDKN2A, EGFR, TP53
40pyomyositis10.4CDH1, CDKN2A, EGFR, TP53
41interstitial lung disease10.4CDKN2A, EGFR, TP53, VEGFA
42onychocytic matricoma10.4MMP2, MMP9, VEGFA
43adenoid squamous cell carcinoma10.4CDKN2A, MMP2, MMP9
44spinal meninges cancer10.4CTNNB1, MMP2, MMP9
45extraocular retinoblastoma10.4CCND1, CDKN1B, CDKN2A, TP53
46tamoxifen-related endometrial lesion10.4CDKN2A, PTGS2, TP53
47integumentary system benign neoplasm10.4CCND1, CDKN1B, CDKN2A, TP53
48cleft palate cardiac defect ectrodactyly10.4CCND1, EGFR, TP53, VEGFA
49post-surgical hypoinsulinemia10.4CCND1, CDKN1B, CDKN2A, TP53
50lacrimal gland adenoid cystic carcinoma10.4CDKN2A, TP53

Graphical network of the top 20 diseases related to Oral Squamous Cell Carcinoma:



Diseases related to oral squamous cell carcinoma

Symptoms & Phenotypes for Oral Squamous Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00055-A-110.2AKT1, CTNNB1, EGFR, HRAS, VEGFC
2GR00381-A-110.1AKT1, CDH1, CDKN1B, CDKN2A, EGFR, HRAS

MGI Mouse Phenotypes related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

41 (show all 25)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000118610.1CASP3, CDKN1B, CDKN2A, CTNNB1, EGFR, TP53
2MP:00053829.8CASP3, CCND1, CDKN1B, CTNNB1, EGFR, HRAS
3MP:00053679.5CASP3, CDKN1B, CTNNB1, EGFR, HRAS, MMP9
4MP:00053809.3AKT1, CDH1, CDKN2A, CTNNB1, EGFR, HOPX
5MP:00053919.2CASP3, CCND1, CDKN1B, CDKN2A, CTNNB1, EGFR
6MP:00053709.2AKT1, CDKN1B, CDKN2A, CTNNB1, EGFR, PTGS2
7MP:00028739.1AKT1, CCND1, CDH1, CTNNB1, EGFR, HRAS
8MP:00053869.0AKT1, CASP3, CCND1, CDKN1B, CDKN2A, CTNNB1
9MP:00053899.0AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
10MP:00020069.0AKT1, CCND1, CDH1, CDKN1B, CDKN2A, CTNNB1
11MP:00053698.7AKT1, CASP3, CDKN1B, CDKN2A, CTNNB1, EGFR
12MP:00053798.7AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
13MP:00030128.7CASP3, CDH1, CDKN1B, CDKN2A, CTNNB1, EGFR
14MP:00053818.7CASP3, CCND1, CDH1, CDKN1B, CDKN2A, CTNNB1
15MP:00053848.6AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
16MP:00053978.5AKT1, CASP3, CCND1, CDKN1B, CDKN2A, CTNNB1
17MP:00053908.5AKT1, CASP3, CCND1, CDKN1B, CDKN2A, CTNNB1
18MP:00053878.5AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
19MP:00053888.4AKT1, CASP3, CCND1, CDKN1B, CDKN2A, CTNNB1
20MP:00053788.3AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
21MP:00107718.3AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
22MP:00053768.3AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
23MP:00036318.1AKT1, CASP3, CCND1, CDKN1B, CDKN2A, CTNNB1
24MP:00107688.0AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A
25MP:00053857.9AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A

Drugs & Therapeutics for Oral Squamous Cell Carcinoma

About this section

Drugs for Oral Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 462)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
FluorouracilapprovedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1185651-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
2
CetuximabapprovedPhase 4, Phase 2, Phase 3, Phase 1752205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
 
Cetuximabum
Cétuximab
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
cetuximab
3
EverolimusapprovedPhase 4, Phase 1, Phase 21940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
4
Fentanylapproved, illicit, investigational, vet_approvedPhase 4, Phase 3821437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
5
Technetium tc 99m sulfur colloidapprovedPhase 422
Synonyms:
 
Technetium 99m sulfur colloid
Technetium Tc-99m Sulfur Colloid
6
Sirolimusapproved, investigationalPhase 4, Phase 1, Phase 2194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
7
CevimelineapprovedPhase 4, Phase 35107233-08-983898, 25137844
Synonyms:
(+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate
(+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate
(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride
107233-08-9
153504-70-2
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
AC1L36EF
AC1L36GD
AC1NR4MS
AC1OCEXD
AF 102B
AF-102B
AF102B
BIDD:GT0265
C10H17NOS
CHEMBL1200362
CID5284532
CID6918023
CID83898
CID83927
Cevimelina
Cevimeline
Cevimeline (INN)
Cevimeline HCl 1/2H2O
Cevimeline [INN]
 
Cevimeline hydrochloride
Cevimeline hydrochloride (USAN)
Cevimeline hydrochloride [USAN]
Cevimeline hydrochloride hemihydrate
Cevimeline hydrochloride hydrate
Cevimeline hydrochloride hydrate (JAN)
Cevimeline.HCl
Cevimelinum
D00661
D07667
DB00185
Evoxac
Evoxac (TN)
FKS-508
Fks 508
HSDB 7286
LS-145782
LS-172037
NCGC00181793-01
SND 5008, AF-102B, FKS-508
SND-5008
SNI-2011
SNK-508
Saligren
Saligren (TN)
Sni 2011
UNII-K9V0CDQ56E
UNII-P81Q6V85NP
cevimeline hydrochloride hydrate
cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1)
8
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
9
Morphineapproved, investigationalPhase 4100757-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
 
Infumorph
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morfina
morphine
nchembio.317-comp1
nchembio.64-comp1
10
Edetic Acidapproved, vet_approvedPhase 49960-00-4, 62-33-96049
Synonyms:
(ethylenedinitrilo)tetraacetic acid, ion(4−)
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate
Acide ethylenediaminetetracetique
Acido edetico
Acidum edeticum
CaEDTA
Calcium Disodium Edetate (JAN)
Calcium Disodium Versenate
Calcium disodium versenate (TN)
 
EDT
EDTA
EDTA, ion(4-)
Edetate Calcium
Edetate calcium disodium (USP)
Ethylenediaminetetraacetate
Ethylenediaminetetraacetic acid
N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine)
acide edetique
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid
11
Mycophenolic acidapprovedPhase 495224280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
12
Cyclosporineapproved, investigational, vet_approvedPhase 492279217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
13
AzathioprineapprovedPhase 4177446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
HMS1920E17
 
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
14
Tacrolimusapproved, investigationalPhase 41102104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
15
Mycophenolate mofetilapproved, investigationalPhase 4952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
16Pharmaceutical SolutionsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 18192
17AnalgesicsPhase 4, Phase 3, Phase 1, Phase 211733
18Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 15806
19Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14962
20Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 14827
21Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 111226
22Autonomic AgentsPhase 4, Phase 3, Phase 2, Phase 110150
23Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 1, Phase 223689
24Cholinergic AgentsPhase 4, Phase 33992
25Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 118340
26Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 17180
27AntimetabolitesPhase 4, Phase 2, Phase 3, Phase 112054
28Immunosuppressive AgentsPhase 4, Phase 2, Phase 3, Phase 113086
29Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 122062
30Antimetabolites, AntineoplasticPhase 4, Phase 2, Phase 3, Phase 17361
31Antirheumatic AgentsPhase 4, Phase 3, Phase 1, Phase 210956
32RadiopharmaceuticalsPhase 4, Phase 1, Phase 2514
33Antifungal AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 13696
34AnestheticsPhase 4, Phase 3, Phase 2, Phase 19596
35Adjuvants, AnesthesiaPhase 4, Phase 3, Phase 11674
36MitomycinsPhase 4, Phase 3, Phase 2240
37Analgesics, OpioidPhase 4, Phase 33238
38Anesthetics, GeneralPhase 4, Phase 3, Phase 12934
39Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113403
40Anesthetics, IntravenousPhase 4, Phase 3, Phase 12538
41NarcoticsPhase 4, Phase 33646
42Chelating AgentsPhase 41423
43DextransPhase 4104
44AnticoagulantsPhase 42623
45Pentetic AcidPhase 499
46Blood SubstitutesPhase 4253
47Technetium Tc 99m PentetatePhase 415
48Plasma SubstitutesPhase 4240
49Calcineurin InhibitorsPhase 41622
50arginineNutraceuticalPhase 4, Phase 2, Phase 1425

Interventional clinical trials:

(show top 50)    (show all 758)
idNameStatusNCT IDPhase
1Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced XerostomiaCompletedNCT00466388Phase 4
2A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer PatientsCompletedNCT01283906Phase 4
3Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer PatientsCompletedNCT02622880Phase 4
4Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the LipCompletedNCT00868088Phase 4
5Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and NeckRecruitingNCT02015650Phase 4
6Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional GastrostomyRecruitingNCT02869321Phase 4
7Sentinel Lymph Node Biopsy Findings in Patients With Breast CancerActive, not recruitingNCT02287675Phase 4
8Stereotactic Body Radiotherapy for Head and Neck TumorsActive, not recruitingNCT01344356Phase 4
9Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive ProtocolTerminatedNCT00866684Phase 4
10TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell CarcinomaUnknown statusNCT01542931Phase 2, Phase 3
11Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIALUnknown statusNCT01039298Phase 3
12Oral Cancer Adjuvant Therapy (OCAT) TrialUnknown statusNCT00193843Phase 3
13Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung CarcinomaUnknown statusNCT01947062Phase 3
14Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth CancerUnknown statusNCT00002747Phase 3
15Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or OropharynxUnknown statusNCT00002702Phase 3
16Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal CancerUnknown statusNCT01434394Phase 2, Phase 3
17Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer TreatmentUnknown statusNCT00935675Phase 3
18S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck CancerUnknown statusNCT00336947Phase 3
19Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck CancerUnknown statusNCT00002659Phase 3
20Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced XerostomiaUnknown statusNCT00081029Phase 3
21PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck CancerUnknown statusNCT00720070Phase 3
22Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma PatientsCompletedNCT00201383Phase 3
23Chemoprevention Study of Oral Cavity Squamous Cell CarcinomaCompletedNCT00201279Phase 3
24Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck PatientsCompletedNCT01439724Phase 3
25Phase II Trial of Allovectin-7® for Head and Neck CancerCompletedNCT00050388Phase 3
26LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based ChemotherapyCompletedNCT01345682Phase 3
27Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCCCompletedNCT00158652Phase 3
28Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck CancerCompletedNCT00003139Phase 3
29Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCCCompletedNCT00162708Phase 2, Phase 3
30Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RTCompletedNCT01931150Phase 3
31Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck CancerCompletedNCT00101582Phase 3
32Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00771641Phase 3
33Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After SurgeryCompletedNCT00424255Phase 3
34Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or LarynxCompletedNCT00004234Phase 3
35Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck CancerCompletedNCT00017511Phase 3
36Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During SurgeryCompletedNCT00002670Phase 3
37Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck CancerCompletedNCT00054561Phase 3
38Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck CancerCompletedNCT00006481Phase 3
39Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00003888Phase 3
40Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck CancerCompletedNCT00003592Phase 3
41Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck CancerCompletedNCT00002533Phase 2, Phase 3
42Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedNCT00003809Phase 3
43Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During SurgeryCompletedNCT00003576Phase 3
44Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck CancerCompletedNCT00064298Phase 3
45Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive TractCompletedNCT00765440Phase 3
46ZD6474 (ZACTIMA™) Phase III Study in EGFR FailuresCompletedNCT00404924Phase 3
47Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck CancerCompletedNCT00608205Phase 3
48Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin CancerCompletedNCT00007631Phase 3
49Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck CancerCompletedNCT00094081Phase 3
50Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck CancerCompletedNCT00006799Phase 3

Search NIH Clinical Center for Oral Squamous Cell Carcinoma

Genetic Tests for Oral Squamous Cell Carcinoma

About this section

Anatomical Context for Oral Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Oral Squamous Cell Carcinoma:

36
Lymph node, Endothelial, Bone, T cells, Neutrophil, Tongue, Testes

Publications for Oral Squamous Cell Carcinoma

About this section

Articles related to Oral Squamous Cell Carcinoma:

(show top 50)    (show all 2103)
idTitleAuthorsYear
1
Long non-coding RNA FTH1P3 facilitates oral squamous cell carcinoma progression by acting as a molecular sponge of miR-224-5p to modulate fizzled 5 expression. (28093311)
2017
2
Icaritin Reduces Oral Squamous Cell Carcinoma Progression via the Inhibition of STAT3 Signaling. (28085115)
2017
3
Isomahanine induces endoplasmic reticulum stress and simultaneously triggers p38A MAPK-mediated apoptosis and autophagy in multidrug-resistant human oral squamous cell carcinoma cells. (28075474)
2017
4
Role of microscopic spread beyond gross disease as an adverse prognostic factor in oral squamous cell carcinoma. (28528911)
2017
5
Icaritin induces mitochondrial apoptosis by up-regulating miR-124 in human oral squamous cell carcinoma cells. (27889233)
2017
6
Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma. (28004115)
2017
7
A comprehensive analysis of candidate gene signatures in oral squamous cell carcinoma. (28043142)
2017
8
The circadian clock gene PER2 plays an important role in tumor suppression through regulating tumor-associated genes in human oral squamous cell carcinoma. (28535015)
2017
9
Combined Analysis of Vascular Endothelial Growth Factor Expression with Cyclooxygenase-2 and Mast Cell Density in Oral Squamous Cell Carcinoma. (27577989)
2017
10
PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma. (28314313)
2017
11
High HMGA2 Expression Correlates with Reduced Recurrence-free Survival and Poor Overall Survival in Oral Squamous Cell Carcinoma. (28373457)
2017
12
High expression of stathmin 1 is a strong prognostic marker in oral squamous cell carcinoma patients treated by docetaxel-containing regimens. (26590596)
2017
13
Upregulated Expression of Transient Receptor Potential Cation Channel Subfamily V Receptors in Mucosae of Patients with Oral Squamous Cell Carcinoma and Patients with a History of Alcohol Consumption or Smoking. (28081185)
2017
14
Transcriptome analysis reveals differentially expressed lncRNAs between oral squamous cell carcinoma and healthy oral mucosa. (28415559)
2017
15
Transforming growth factor-I^1 suppresses bone morphogenetic protein-2-induced mesenchymal-epithelial transition in HSC-4 human oral squamous cell carcinoma cells via Smad1/5/9 pathway suppression. (28035402)
2017
16
Saliva protein biomarkers and oral squamous cell carcinoma. (28039438)
2017
17
Long noncoding RNA HAS2-AS1 mediates hypoxia-induced invasiveness of oral squamous cell carcinoma. (28485478)
2017
18
Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma. (27923688)
2017
19
LncRNA, TUG1 regulates the oral squamous cell carcinoma progression possibly via interacting with Wnt/I^-catenin signaling. (28119088)
2017
20
KLK4 silencing inhibits the growth of oral squamous cell carcinoma through Wnt/I^-catenin signaling pathway. (28150891)
2017
21
Expression of hypoxia-induced factor-1 alpha in early-stage and in metastatic oral squamous cell carcinoma. (28381176)
2017
22
Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. (27922697)
2017
23
Downregulation of miR-377 Promotes Oral Squamous Cell Carcinoma Growth and Migration by Targeting HDAC9. (28267394)
2017
24
The expression and significance of the HOXA7 gene in oral squamous cell carcinoma. (28529281)
2017
25
Saliva protein biomarkers to detect oral squamous cell carcinoma in a high-risk population in Taiwan. (27663741)
2016
26
Expression profiles of MGMT, p16, and APC genes in tumor and matching surgical margin from patients with oral squamous cell carcinoma. (27494112)
2016
27
Nucleotide-binding oligomerization domain 2 (NOD2) activation induces apoptosis of human oral squamous cell carcinoma cells. (26332444)
2016
28
Clinicopathological implications of vascular endothelial growth factor 165b expression in oral squamous cell carcinoma stroma. (27221145)
2016
29
Recruitment of Tiam1 to Semaphorin 4D Activates Rac and Enhances Proliferation, Invasion, and Metastasis in Oral Squamous Cell Carcinoma. (28038319)
2016
30
Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis. (26992905)
2016
31
Detection of survivin, carcinoembryonic antigen and Erbb2 level in oral squamous cell carcinoma patients. (27662323)
2016
32
Overexpression of proteasomal activator PA28I+ serves as a prognostic factor in oral squamous cell carcinoma. (26892607)
2016
33
MALDI imaging reveals NCOA7 as a potential biomarker in oral squamous cell carcinoma arising from oral submucous fibrosis. (27509054)
2016
34
Association of the XPD and XRCC3 gene polymorphisms with oral squamous cell carcinoma in a Northeastern Brazilian population: A pilot study. (26742000)
2016
35
Adenosine Deaminase - a Novel Diagnostic and Prognostic Biomarker for Oral Squamous Cell Carcinoma. (27221867)
2016
36
Micronome revealed miR-19a/b as key regulator of SOCS3 during cancer related inflammation of oral squamous cell carcinoma. (27581787)
2016
37
Signal regulatory protein I+ associated with the progression of oral leukoplakia and oral squamous cell carcinoma regulates phenotype switch of macrophages. (27793032)
2016
38
Crosstalk between the HIF-1 and toll-like receptor/nuclear factor-I_B pathways in the oral squamous cell carcinoma microenvironment. (27191981)
2016
39
Salivary Levels of ErbB2 and CEA in Oral Squamous Cell Carcinoma Patients. (27165212)
2016
40
Validation of housekeeping genes for the normalization of RT-qPCR expression studies in oral squamous cell carcinoma cell line treated by 5 kinds of chemotherapy drugs. (28040059)
2016
41
Osteoactivin Promotes Migration of Oral Squamous Cell Carcinomas. (26636434)
2016
42
Genome-wide haplotype association analysis identifies SERPINB9, SERPINE2, GAK, and HSP90B1 as novel risk genes for oral squamous cell carcinoma. (26318431)
2016
43
Association of OCT4, SOX2, and NANOG expression with oral squamous cell carcinoma progression. (26211876)
2016
44
Association of Poly (ADP-Ribose) Polymerase 1 Variants with Oral Squamous Cell Carcinoma Susceptibility in a South Indian Population. (27644669)
2016
45
Is an Elective Neck Dissection Necessary for All Cases of N0 Oral Squamous Cell Carcinoma? -Elective Neck Dissection may be Performed for Tongue Cancer with Tumor Thickness More than 4 mm. (27628601)
2016
46
Overexpression of I^-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma. (27529071)
2016
47
Tachykinin Receptor 3 Distribution in Human Oral Squamous Cell Carcinoma. (27919954)
2016
48
Absence of high-risk HPV 16 and 18 in Chinese patients with oral squamous cell carcinoma and oral potentially malignant disorders. (27206495)
2016
49
Immunohistochemical Evaluation of Mast Cells in Leukoplakia and Oral Squamous Cell Carcinoma. (27656549)
2016
50
Hypoxia inducible factor: a potential prognostic biomarker in oral squamous cell carcinoma. (26880584)
2016

Variations for Oral Squamous Cell Carcinoma

About this section

Cosmic variations for Oral Squamous Cell Carcinoma:

8 (show top 50)    (show all 331)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM6240EGFRupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.2369C>Tp.T790M12
2COSM99622NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.4016G>Cp.G1339A12
3COSM44310TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.738G>Ap.M246I12
4COSM10648TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.524G>Ap.R175H12
5COSM11196TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.734G>Tp.G245V12
6COSM763PIK3CAupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.1633G>Ap.E545K12
7COSM24802FGFR3upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.2089G>Tp.G697C12
8COSM33692HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.185A>Gp.E62G12
9COSM43947TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.614A>Gp.Y205C12
10COSM44393TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.821T>Cp.V274A12
11COSM498HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.182A>Tp.Q61L12
12COSM764PIK3CAupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.1634A>Gp.E545G12
13COSM43582TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.454C>Tp.P152S12
14COSM483HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.35G>Tp.G12V12
15COSM29446FGFR3upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.753C>Tp.H251H12
16COSM44226TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.380C>Tp.S127F12
17COSM99653NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.3835C>Tp.R1279C12
18COSM10654TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.637C>Tp.R213*12
19COSM10704TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.844C>Tp.R282W12
20COSM10672TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.577C>Tp.H193Y12
21COSM10941TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.730G>Ap.G244S12
22COSM10656TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.742C>Tp.R248W12
23COSM10728TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.839G>Ap.R280K12
24COSM43635TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.536A>Tp.H179L12
25COSM1667029NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.666C>Ap.C222*12
26COSM44126TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.507G>Ap.M169I12
27COSM10790TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.455C>Tp.P152L12
28COSM43868TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.689C>Tp.T230I12
29COSM12504CDKN2Aupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.247C>Tp.H83Y12
30COSM44335TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.958A>Tp.K320*12
31COSM44091TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.746G>Ap.R249K12
32COSM11063TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.711G>Tp.M237I12
33COSM1737921CDKN2Aupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.124A>Cp.N42H12
34COSM44577TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.921A>Gp.A307A12
35COSM3722007HCN1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.808C>Tp.R270*12
36COSM488HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.37G>Tp.G13C12
37COSM99939NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.5529G>Ap.W1843*12
38COSM10834TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.711G>Ap.M237I12
39COSM45099TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.924G>Ap.L308L12
40COSM3724382NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.6738C>Gp.H2246Q12
41COSM521KRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.35G>Ap.G12D12
42COSM3724387CASP8upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.415C>Tp.Q139*12
43COSM480HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.34G>Ap.G12S12
44COSM481HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.34G>Tp.G12C12
45COSM3723031PHF14upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.344A>Gp.K115R12
46COSM777PIK3CAupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.3145G>Ap.G1049S12
47COSM12764EGFRupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.2569G>Ap.G857R12
48COSM489HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.38G>Tp.G13V12
49COSM10867TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.797G>Ap.G266E12
50COSM11073TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.1024C>Tp.R342*12

Copy number variations for Oral Squamous Cell Carcinoma from CNVD:

6 (show top 50)    (show all 164)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
141848102460000038000000DeletionOral squamous cell carcinoma
24970611110400000121200000DeletionOral squamous cell carcinoma
35098811121200000130800000DeletionOral squamous cell carcinoma
451497111270000016200000DeletionOral squamous cell carcinoma
557445116340000077100000AmplificationCCND1Oral squamous cell carcinoma
657446116340000077100000AmplificationEMS1Oral squamous cell carcinoma
757448116340000077100000AmplificationFGF3Oral squamous cell carcinoma
857449116340000077100000AmplificationFGF4Oral squamous cell carcinoma
957450116340000077100000AmplificationPPP1CAOral squamous cell carcinoma
1057451116340000077100000AmplificationTAOS1Oral squamous cell carcinoma
1158782116947136769490165AmplificationORAOV1Oral squamous cell carcinoma
12740651314500000DeletionOral squamous cell carcinoma
137417913101700000110300000DeletionOral squamous cell carcinoma
14751701317900000115169878Noncopy numberrandom LOHOral squamous cell carcinoma
1576133132780000055300000DeletionOral squamous cell carcinoma
1676134132780000087700000DeletionOral squamous cell carcinoma
1776220132890000040100000DeletionOral squamous cell carcinoma
1876534133220000040100000DeletionOral squamous cell carcinoma
1976709133550000040100000DeletionOral squamous cell carcinoma
2077109134010000059600000DeletionOral squamous cell carcinoma
2178640135530000073300000DeletionOral squamous cell carcinoma
2279281136860000087700000DeletionOral squamous cell carcinoma
2379539137330000079000000DeletionOral squamous cell carcinoma
2479879137900000087700000DeletionOral squamous cell carcinoma
2580342139000000098200000DeletionOral squamous cell carcinoma
26806291395000000110300000DeletionOral squamous cell carcinoma
27806321395000000115169878DeletionOral squamous cell carcinoma
2880634139500000098200000DeletionOral squamous cell carcinoma
2983034141910000033300000DeletionOral squamous cell carcinoma
3084231142460000033300000DeletionOral squamous cell carcinoma
3185052143780000050900000DeletionOral squamous cell carcinoma
3286340145810000067900000DeletionOral squamous cell carcinoma
3386341145810000073800000DeletionOral squamous cell carcinoma
3487452147380000079300000DeletionOral squamous cell carcinoma
358913315119000000Noncopy numberrandom LOHOral squamous cell carcinoma
3690246152070000040100000DeletionOral squamous cell carcinoma
3791779153360000040100000DeletionOral squamous cell carcinoma
3891783153360000044800000DeletionOral squamous cell carcinoma
3992363154010000049500000DeletionOral squamous cell carcinoma
4092861154480000049500000DeletionOral squamous cell carcinoma
4193371155290000072700000DeletionOral squamous cell carcinoma
4295627157830000089100000DeletionOral squamous cell carcinoma
4395629157830000098500000DeletionOral squamous cell carcinoma
4410675417116000000DeletionOral squamous cell carcinoma
4510683117124000000Noncopy numberrandom LOHOral squamous cell carcinoma
4610690717181195210DeletionOral squamous cell carcinoma
47106970171070000050200000DeletionOral squamous cell carcinoma
48109058172400000081195210Noncopy numberrandom LOHOral squamous cell carcinoma
49112186173810000057600000DeletionOral squamous cell carcinoma
50114590175020000070900000DeletionOral squamous cell carcinoma

Expression for genes affiliated with Oral Squamous Cell Carcinoma

About this section
Search GEO for disease gene expression data for Oral Squamous Cell Carcinoma.

Pathways for genes affiliated with Oral Squamous Cell Carcinoma

About this section

Pathways related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 135)
idSuper pathwaysScoreTop Affiliating Genes
110.2VEGFA, VEGFC
210.1CCND1, CDKN1B, TP53
310.1AKT1, CDKN1B, HRAS
410.1AKT1, CDKN1B, HRAS
510.1AKT1, HRAS, TP53
610.1CCND1, MMP2, MMP9
7
Show member pathways
10.1AKT1, CCND1, CDKN1B
8
Show member pathways
10.1CCND1, EGFR, VEGFA
910.1CCND1, CDKN1B, PTGS2
1010.1CASP3, HRAS, MMP2
11
Show member pathways
10.1AKT1, CDKN2A, TP53
1210.1AKT1, CDKN1B, VEGFA
1310.1CASP3, EGFR, HRAS
1410.0CTNNB1, EGFR, TP53
1510.0EGFR, MMP2, MMP9
1610.0AKT1, CDH1, MMP9
1710.0CDH1, CTNNB1, EGFR
1810.0CDH1, CTNNB1, EGFR
1910.0PTGS2, TP53, VEGFA
20
Show member pathways
10.0AKT1, EGFR, TP53
2110.0AKT1, CDKN1B, CTNNB1
2210.0AKT1, CDKN1B, CTNNB1
2310.0AKT1, CDH1, EGFR
24
Show member pathways
10.0AKT1, MMP9, VEGFA
2510.0AKT1, MMP9, VEGFA
2610.0AKT1, MMP2, MMP9
2710.0AKT1, MMP2, MMP9
2810.0CTNNB1, VEGFA, VEGFC
29
Show member pathways
10.0AKT1, CASP3, TP53
3010.0AKT1, CCND1, CTNNB1
3110.0AKT1, CCND1, CTNNB1
3210.0AKT1, CCND1, CTNNB1
3310.0CDKN1B, CDKN2A, HRAS, TP53
34
Show member pathways
10.0CCND1, CDKN1B, CDKN2A, TP53
3510.0KRT19, PTGS2, TP53
369.9AKT1, CCND1, CDH1, HRAS
379.9CASP3, EGFR, HRAS, TP53
389.9CDKN2A, TP53, VEGFA, VEGFC
39
Show member pathways
9.9AKT1, CCND1, CDKN2A, TP53
409.9AKT1, EGFR, HRAS, TP53
419.9AKT1, EGFR, HRAS, TP53
429.9AKT1, CDH1, EGFR, HRAS
439.9AKT1, CCND1, CDKN1B, EGFR
449.9CDH1, CTNNB1, MMP2, MMP9
459.9AKT1, CDH1, CTNNB1, HRAS
46
Show member pathways
9.9AKT1, CASP3, HRAS, TP53
47
Show member pathways
9.9AKT1, CCND1, CTNNB1, HRAS
489.9AKT1, CASP3, CDKN1B, TP53
499.9AKT1, CDKN1B, EGFR, VEGFA
509.9AKT1, CCND1, CDH1, CTNNB1

GO Terms for genes affiliated with Oral Squamous Cell Carcinoma

About this section

Cellular components related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1catenin complexGO:001634211.0CDH1, CTNNB1
2flotillin complexGO:001660010.2CDH1, CTNNB1
3cytoplasmGO:00057378.5AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A

Biological processes related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 51)
idNameGO IDScoreTop Affiliating Genes
1mitotic G1 DNA damage checkpointGO:003157111.0CCND1, TP53
2cellular response to indole-3-methanolGO:007168111.0CDH1, CTNNB1
3positive regulation of mast cell chemotaxisGO:006075411.0VEGFA, VEGFC
4positive regulation of cell migration involved in sprouting angiogenesisGO:009005010.9PTGS2, VEGFA
5positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycleGO:003165910.9AKT1, EGFR
6positive regulation of cellular component movementGO:005127210.9PDPN, VEGFA
7extracellular matrix disassemblyGO:002261710.9CDH1, MMP2, MMP9
8negative regulation of cyclin-dependent protein serine/threonine kinase activityGO:004573610.9CASP3, CDKN1B, CDKN2A
9positive regulation of MAP kinase activityGO:004340610.8EGFR, HRAS, VEGFA
10cellular response to organic cyclic compoundGO:007140710.8AKT1, CASP3, CDKN1B
11Ras protein signal transductionGO:000726510.8CDKN2A, HRAS, TP53
12cellular response to cadmium ionGO:007127610.8AKT1, EGFR, MMP9
13cellular response to reactive oxygen speciesGO:003461410.8AKT1, EGFR, MMP9
14embryo implantationGO:000756610.8MMP2, MMP9, PTGS2
15cell cycle arrestGO:000705010.8CDKN1B, CDKN2A, HRAS, TP53
16cellular response to growth factor stimulusGO:007136310.8AKT1, CTNNB1, EGFR
17positive regulation of neuron apoptotic processGO:004352510.8CASP3, CTNNB1, TP53
18positive regulation of blood vessel endothelial cell migrationGO:004353610.8AKT1, VEGFA, VEGFC
19positive regulation of neuroblast proliferationGO:000205210.8CTNNB1, VEGFA, VEGFC
20cellular response to mechanical stimulusGO:007126010.8AKT1, EGFR, PTGS2
21positive regulation of endothelial cell proliferationGO:000193810.8AKT1, VEGFA, VEGFC
22negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:004315410.8AKT1, PTGS2, VEGFA
23positive regulation of peptidyl-serine phosphorylationGO:003313810.8AKT1, PTGS2, VEGFA
24positive regulation of nitric oxide biosynthetic processGO:004542910.7AKT1, EGFR, PTGS2
25G1/S transition of mitotic cell cycleGO:000008210.7AKT1, CCND1, CDKN1B, CDKN2A
26positive regulation of smooth muscle cell proliferationGO:004866110.7AKT1, EGFR, PTGS2
27positive regulation of cell migrationGO:003033510.7EGFR, HRAS, MMP9, VEGFA
28positive regulation of epithelial cell proliferationGO:005067910.7EGFR, HRAS, VEGFA, VEGFC
29positive regulation of vasoconstrictionGO:004590710.7AKT1, EGFR, PTGS2
30cellular response to hypoxiaGO:007145610.7AKT1, PTGS2, TP53, VEGFA
31angiogenesisGO:000152510.7MMP2, PTGS2, VEGFA, VEGFC
32response to glucocorticoidGO:005138410.7CASP3, CCND1, PTGS2
33lung developmentGO:003032410.6CTNNB1, EGFR, PDPN, VEGFA
34response to X-rayGO:001016510.6CASP3, CCND1, TP53
35regulation of cell proliferationGO:004212710.6CDKN1B, CTNNB1, EGFR, PTGS2
36response to UV-AGO:007014110.6AKT1, CCND1, EGFR
37positive regulation of protein phosphorylationGO:000193410.4AKT1, CCND1, EGFR, HRAS, MMP9, VEGFA
38response to hypoxiaGO:000166610.4CASP3, CDKN1B, MMP2, VEGFA, VEGFC
39cell proliferationGO:000828310.4AKT1, CTNNB1, EGFR, HRAS, PDPN, TP53
40positive regulation of transcription, DNA-templatedGO:004589310.3AKT1, CDH1, CDKN2A, CTNNB1, EGFR, TP53
41response to organic cyclic compoundGO:001407010.3CASP3, CCND1, CDKN1B, EGFR, PTGS2
42negative regulation of cell proliferationGO:000828510.3CDKN1B, CDKN2A, CTNNB1, HRAS, PTGS2, TP53
43negative regulation of apoptotic processGO:004306610.3AKT1, CASP3, CDKN1B, EGFR, MMP9, TP53
44response to organic substanceGO:001003310.3AKT1, CASP3, CCND1, CDH1, PTGS2
45response to estradiolGO:003235510.2CASP3, CCND1, CDKN1B, CTNNB1, EGFR, PTGS2
46positive regulation of transcription from RNA polymerase II promoterGO:004594410.2AKT1, CDKN2A, CTNNB1, EGFR, HRAS, TP53
47positive regulation of apoptotic processGO:004306510.2AKT1, CASP3, CDKN2A, CTNNB1, MMP9, PTGS2
48multicellular organism developmentGO:000727510.1AKT1, EGFR, HOPX, PDPN, TP53, VEGFA
49response to drugGO:004249310.1CASP3, CCND1, CDH1, CDKN1B, CTNNB1, PTGS2
50positive regulation of cell proliferationGO:000828410.1CCND1, CDKN1B, CTNNB1, EGFR, HRAS, PTGS2

Molecular functions related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nitric-oxide synthase regulator activityGO:003023511.0AKT1, EGFR
2cyclin-dependent protein serine/threonine kinase inhibitor activityGO:000486110.9CASP3, CDKN1B, CDKN2A
3enzyme bindingGO:001989910.4AKT1, CCND1, CTNNB1, EGFR, PTGS2, TP53
4protein kinase bindingGO:001990110.0AKT1, CCND1, CDKN1B, CDKN2A, CTNNB1, EGFR
5protein phosphatase bindingGO:00199039.9CDKN1B, CTNNB1, EGFR, TP53
6protein bindingGO:00055158.4AKT1, CASP3, CCND1, CDH1, CDKN1B, CDKN2A

Sources for Oral Squamous Cell Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet